UK-CAB 66: AIDS 2018 feedback, future ART, cure research
Friday 3 August 2018
- Register for this meeting (now closed)
- Venue
- Hotel Details
- Expenses
Programme
| 09.15-09.30 | Arrival, tea and refreshments |
| 09.30-10.00 | Welcome and introductions:
UK-CAB updates and company pre-meeting |
| 10.00-11.30 | Company meeting: Janssen |
| 11.30-11.45 | Break |
| 11.45-12.45 | RIVER Cure Study – Dr Sarah Fidler |
| 12.45-14.00 | Lunch – @ Marquis Cornwallis pub |
| 14.00-14.45 | Future treatments – Damian Kelly |
| 14.45-15.30 | AIDS 2018 conference feedback
Garry Brough/Lisa Thorley |
| 15.30-15.45 | Break |
| 15.45-17.00 | Community rep feedback:
MRC CTU PPI – Ben Cromarty Discussion of meeting updates |
| 17.00 | Meeting close |
Slides and meeting report
UK-CAB 66 meeting report Aug 2018 (Word .doc) – confidential, available to members only
Slides on RIVER study (PDF).
Slides from Janssen presentation (PDF) – confidential, available to members only
Background reading and videos/webcasts
RIVER study
- RIVER results at AIDS 2018 presentation
http://i-base.info/htb/34618
Future drugs
- i-Base pipeline report 2018
http://i-base.info/htb/34488
AIDS 2018 feedback
- Webcast of PARTNER2 results at AIDS 2018.
https://tinyurl.com/y6tweapv
Janssen
- Results from Phase 2 vaccine presented at AIDS 2018
https://youtu.be/NnwkRwgcFLQ?t=953 - New contraindication against using darunavir/cobicistat during pregnancy
http://i-base.info/htb/34337 - Boosted darunavir is associated with higher cardiovascular risk in D:A:D study
http://i-base.info/htb/34218
Financial support
The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year.
This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering. The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.
Companies that develop and market medicines have a responsibility to actively engage with advocacy organisations. HIV positive people and their advocates should also be able to ask manufacturers directly about the safety and efficacy of their products. We should be involved in their proposals for future research.
For a list of companies that support the UK-CAB please see the “about us” page.